A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 1.94 USD -0.51% Market Closed
Market Cap: 70.2m USD
Have any thoughts about
Armata Pharmaceuticals Inc?
Write Note

Armata Pharmaceuticals Inc
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Armata Pharmaceuticals Inc
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Other Current Assets
$3m
CAGR 3-Years
50%
CAGR 5-Years
18%
CAGR 10-Years
22%
Abbvie Inc
NYSE:ABBV
Other Current Assets
$4.6B
CAGR 3-Years
2%
CAGR 5-Years
17%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Current Assets
$3.1B
CAGR 3-Years
7%
CAGR 5-Years
-2%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Current Assets
$449.2m
CAGR 3-Years
-1%
CAGR 5-Years
21%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Current Assets
$412m
CAGR 3-Years
-5%
CAGR 5-Years
13%
CAGR 10-Years
14%
No Stocks Found

Armata Pharmaceuticals Inc
Glance View

Market Cap
70.2m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
2.18 USD
Undervaluation 11%
Intrinsic Value
Price
A

See Also

What is Armata Pharmaceuticals Inc's Other Current Assets?
Other Current Assets
3m USD

Based on the financial report for Sep 30, 2024, Armata Pharmaceuticals Inc's Other Current Assets amounts to 3m USD.

What is Armata Pharmaceuticals Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
22%

Over the last year, the Other Current Assets growth was -26%. The average annual Other Current Assets growth rates for Armata Pharmaceuticals Inc have been 50% over the past three years , 18% over the past five years , and 22% over the past ten years .

Back to Top